Characteristics | Repaglinide and clopidogrel group | Mitiglinide and clopidogrel group | Repaglinide group | p value |
---|---|---|---|---|
(N = 15) | (N = 15) | (N = 15) | ||
Age | 75.6 ± 12.2 | 70.4 ± 11.5 | 76.1 ± 10.9 | 0.332* |
Male (%) | 10 (66.7%) | 12 (80.0%) | 10 (66.7%) | 0.649*** |
BMI | 23.6 ± 3.2 | 24.4 ± 2.9 | 23.2 ± 3.9 | 0.598* |
HbA1c | 9.3 ± 2.0 | 9.5 ± 2.0 | 9.7 ± 2.6 | 0.851* |
Serum creatinine | 0.84 ± 0.32 | 0.80 ± 0.16 | 0.76 ± 0.16 | 0.594* |
Liver function (Grade 1 [CTCAE ver.4.0]: AST, ALT, or T-Bil) | 4 (26.7%) | 5 (33.3%) | 3 (20.0%) | 0.912** |
Calorie intake (kcal) | 1325.9 ± 283.3 | 1497.0 ± 247.5 | 1517.2 ± 168.7 | 0.065* |
Concomitant agent use (oral hypoglycemic drugs, insulin, GLP-1 agonists, and/or agents which may enhance the hypoglycemic action of repaglinide or mitiglinide, other than the above) | 10 (67.7%) | 9 (60.0%) | 9 (60.0%) | 0.910*** |